BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $228 | -58.3% | 3,350 | -50.0% | 0.01% | -59.1% |
Q2 2023 | $547 | -48.9% | 6,698 | -53.6% | 0.02% | -50.0% |
Q1 2023 | $1,071 | -14.0% | 14,440 | -3.9% | 0.04% | -20.0% |
Q4 2022 | $1,245 | -99.9% | 15,020 | +251.6% | 0.06% | +17.0% |
Q3 2022 | $1,213,000 | -36.6% | 4,272 | -22.6% | 0.05% | -17.5% |
Q2 2022 | $1,912,000 | -18.2% | 5,516 | +2.2% | 0.06% | +3.6% |
Q1 2022 | $2,338,000 | -21.5% | 5,398 | -6.2% | 0.06% | -9.8% |
Q4 2021 | $2,977,000 | +17.3% | 5,754 | +9.8% | 0.06% | +7.0% |
Q3 2021 | $2,539,000 | +13.9% | 5,240 | +5.8% | 0.06% | +32.6% |
Q2 2021 | $2,229,000 | +41.4% | 4,951 | +20.0% | 0.04% | +34.4% |
Q1 2021 | $1,576,000 | +19.7% | 4,127 | -0.5% | 0.03% | +18.5% |
Q4 2020 | $1,317,000 | +28.2% | 4,147 | 0.0% | 0.03% | +12.5% |
Q3 2020 | $1,027,000 | +5.8% | 4,147 | +12.8% | 0.02% | 0.0% |
Q2 2020 | $971,000 | +36.0% | 3,678 | -2.3% | 0.02% | +20.0% |
Q1 2020 | $714,000 | -14.9% | 3,766 | -1.5% | 0.02% | +11.1% |
Q4 2019 | $839,000 | +8.5% | 3,824 | -3.2% | 0.02% | 0.0% |
Q3 2019 | $773,000 | -7.0% | 3,951 | -0.9% | 0.02% | 0.0% |
Q2 2019 | $831,000 | +53.9% | 3,985 | -27.3% | 0.02% | +63.6% |
Q2 2015 | $540,000 | -6.1% | 5,485 | -4.4% | 0.01% | +10.0% |
Q1 2015 | $575,000 | +8.1% | 5,737 | -0.3% | 0.01% | +11.1% |
Q4 2014 | $532,000 | – | 5,754 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |